BioCentury | Mar 2, 2015
Clinical News

Astragraf XL tacrolimus: Phase IIIb data

The open-label, international Phase IIIb DIAMOND trial in 893 patients showed that once-daily low-dose (0.15-0.175 mg/kg) Advagraf in combination with Simulect basiliximab and mycophenolate mofetil (MMF) met the primary endpoint of increasing GFR as measured...
BioCentury | Dec 11, 2014
Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Breast cancer Breast cancer anti-estrogen resistance 4 (BCAR4) In vitro and mouse studies suggest inhibiting BCAR4 could help treat metastatic breast cancer. In primary breast...
BioCentury | May 9, 2011
Clinical News

Advagraf tacrolimus: Phase IIIb data

The open-label, international Phase IIIb OSAKA trial in 1,251 adult kidney transplant patients showed that 0.2 mg/kg/day Advagraf once daily was non-inferior to the same daily dose of twice-daily Prograf tacrolimus over 6 months in...
BioCentury | Jul 31, 2006
Clinical News

Prograf MR tacrolimus: Phase III data

One-year data from an open-label Phase III trial in 638 adult kidney transplant recipients showed that both Prograf MR and standard Prograf were non-inferior to cyclosporine in various parameters. Specifically, Prograf patients had significantly less...
Items per page:
1 - 4 of 4